Persistent inflammation may influence neurodegeneration through microglial activation, yet evidence remains hypothesis driven ...
Livewire Markets on MSN
Is CSL giving you a headache? Here are 6 ASX biotech firms for the watchlist
Two experts share the Aussie names with big catalysts on the horizon.
Kasey Keller, the USMNT goalkeeper through four FIFA World Cups, discusses his non-Hodgkins lymphoma diagnosis in 2010 and what the soccer legend has gone through since.
The FDA Center for Drug Evaluation and Research has accepted a letter of intent for the first biomarker for idiopathic ...
“Facial lymphatic brushing gently stimulates lymph flow, helping to move excess fluid, reduce puffiness, and support the skin ...
A supplement made from broccoli, green tea, and turmeric has slowed the rise of a prostate cancer blood marker in men monitored for early disease. That slowdown reframes how long some patients may ...
First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY ...
Daniel Kirby, Chief Commercial Officer of Iovance, stated, “The real world Amtagvi data with impressive response rates, paired with unprecedented five-year durability and survival data, demonstrate a ...
So normally the way we give CAR-T is that we take out the T-cells from patients, then we engineer them to attack them myeloma, and then we give them back to them. But that takes time because ...
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal ...
Discover how Laverdia CA1 (verdinexor) treats canine lymphoma. Learn about the mechanism of action, handling precautions, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results